TSHR; NPSR1; CXCR1; NMUR2; | |
ADRA2C; ADRA2A; GPBAR1; DRD4; | |
ALPI; RECQL; PLA2G1B; TDP1; PKM; PIK3R1; GLO1; HSD11B1; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; AKR1B10; ALOX12; NOX4; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; CES2; CD38; | |
PTPN1; PTPN11; PTPN6; CDC25B; PTPRF; PTPN2; ACP1; | |
ACHE; GAA; | |
NEK6; PKN1; MET; CSNK2A1; AKT1; DAPK1; NEK2; FLT3; CAMK2B; SRC; IGF1R; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; PTK2; AXL; KDR; | |
CA3; CA14; CA7; CA1; CA12; CA9; CA4; CA6; CA2; CA5B; CA5A; | |
NR1H4; | |
RORC; | |
ESR2; | |
KDM4E; | |
MAOA; ALOX5; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
LMNA; MCL1; MAPT; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
Protein Phosphatase | PTPN6 | Protein-tyrosine phosphatase 1C | P29350 | CHEMBL3166 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.349E-13 | 1.279E-10 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, PARP1, PTPN1, RORC, TNKS, TP53 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.003E-09 | 2.415E-07 | ADRA2A, AURKB, CA2, CA7, CD38, HIF1A, KDR, MAPK1, NEK2, NPSR1, NR1H4, PARP1, PLA2G1B, PTPN6, SRC, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.345E-09 | 5.210E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.008E-09 | 1.008E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.018E-08 | 1.732E-06 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, PTPN11, PTPN6, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.157E-08 | 1.908E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.022E-08 | 3.057E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.224E-08 | 3.250E-06 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 2.712E-08 | 3.786E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, TNKS |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.786E-08 | 3.864E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.850E-08 | 5.174E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.104E-08 | 6.615E-06 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, TNKS, TNKS2 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.309E-07 | 1.493E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.584E-07 | 1.778E-05 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.822E-07 | 2.003E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.076E-07 | 2.238E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.491E-07 | 2.595E-05 | ADRA2A, AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PTPN11, PTPN2, PYGL |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.924E-07 | 4.682E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.584E-07 | 6.005E-05 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 7.192E-07 | 6.418E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.088E-06 | 9.215E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.162E-06 | 9.716E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.286E-06 | 1.065E-04 | ACP1, CDC25B, PTPN1, PTPN11, PTPN2, PTPN6, PTPRF |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.303E-06 | 1.075E-04 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1, PTPN11 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 1.589E-06 | 1.272E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.639E-06 | 1.308E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | Unclassified; | GO:0032403; protein complex binding | 1.692E-06 | 1.340E-04 | ACHE, ADRA2A, APEX1, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, PIK3R1, PKM, PTPN1, PTPN11, PTPN2, PTPRF, SRC, TSHR |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.917E-06 | 1.485E-04 | AKT1, APEX1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MAPK1, MCL1, MMP2, MPO, NFKB1, NOX4, PARP1, PKM, PTPN11, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.266E-06 | 2.362E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.989E-06 | 2.811E-04 | AKT1, APEX1, APP, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, RORC, SRC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.953E-06 | 3.435E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.023E-06 | 3.461E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032502; developmental process | GO:0007568; aging | 5.556E-06 | 3.722E-04 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 7.457E-06 | 4.862E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 9.070E-06 | 5.792E-04 | HIF1A, MCL1, PARP1 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.070E-06 | 5.792E-04 | ADRA2A, ADRA2C, DRD4 |
MF | GO:0003824; catalytic activity | GO:0004726; non-membrane spanning protein tyrosine phosphatase activity | 9.070E-06 | 5.792E-04 | ACP1, PTPN11, PTPN2 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.110E-05 | 6.924E-04 | AKR1B1, AKT1, ALOX5, APEX1, AURKB, CAMK2B, CDC25B, CDK1, CSNK2A1, ESR2, GSK3B, HIF1A, L3MBTL1, LMNA, MAPK1, MCL1, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PARP1, PIM1, PKN1, POLB, PTPN11, PTPN2, RECQL, RORC, SMN1, SMN2, SRC, STAT6, TNKS, TP53 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.355E-05 | 8.406E-04 | NR1H4, PLA2G1B, PYGL |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.416E-05 | 8.709E-04 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.416E-05 | 8.709E-04 | APP, GSK3B, IGF1R, PARP1 |
MF | GO:0005488; binding | GO:0030971; receptor tyrosine kinase binding | 1.449E-05 | 8.860E-04 | PIK3R1, PTPN1, PTPN11, PTPN2, TP53 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.462E-05 | 8.893E-04 | AKT1, HIF1A, MCL1, MMP9, PTPN1, SRC |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.645E-05 | 9.921E-04 | AKT1, MAPT, PTPN1, TP53 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.068E-05 | 1.207E-03 | CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, PTPN6, SRC |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.197E-05 | 1.266E-03 | AXL, MET, NOX4, PIK3R1, PTK2, PTPN11, SRC |
BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.207E-05 | 1.268E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.495E-05 | 1.411E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 2.511E-05 | 1.416E-03 | ACP1, AKR1B1, AKR1B10, AKT1, ALOX12, ALOX15, ALOX5, APP, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDC25B, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, LMNA, MAPK1, MAPT, MCL1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PTK2, PTPN1, PTPN11, PTPN2, PTPN6, PYGL, SMN1, SMN2, SRC, STAT6, TNKS, TNKS2, TP53, XDH |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.640E-05 | 1.482E-03 | IGF1R, PIK3R1, PTPN11 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.840E-05 | 1.566E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0033277; abortive mitotic cell cycle | 3.040E-05 | 1.639E-03 | PTPN11, PTPN6 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.040E-05 | 1.639E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.040E-05 | 1.639E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.040E-05 | 1.639E-03 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.506E-05 | 1.867E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.506E-05 | 1.867E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.631E-05 | 1.924E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 3.750E-05 | 1.972E-03 | AKT1, HIF1A, NFKB1, PTPN2, SRC |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 4.329E-05 | 2.234E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 4.539E-05 | 2.317E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.544E-05 | 2.317E-03 | AXL, FLT3, HIF1A, PKN1, POLB, PTPN11 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.946E-05 | 2.482E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.599E-05 | 2.771E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 5.928E-05 | 2.894E-03 | AKT1, ALK, APP, CYP1B1, ESR2, MAPK1, NFKB1, NR1H4, PIM1, PLA2G1B |
BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 6.025E-05 | 2.932E-03 | AKR1B1, AKT1, CA9, CD38, CSNK2A1, PARP1, SRC |
BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 6.148E-05 | 2.981E-03 | ADRA2C, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, MAPT, NFKB1, NR1H4, PARP1, PIM1, SRC, STAT6 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.417E-05 | 3.098E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 6.833E-05 | 3.256E-03 | GSK3B, MAPT, MCL1, PARP1, TP53 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 6.879E-05 | 3.267E-03 | ADRA2A, AKT1, APP, CDK1, DAPK1, GSK3B, MAPT, PTK2, SRC, XDH |
BP | GO:0002376; immune system process | GO:0061515; myeloid cell development | 6.976E-05 | 3.274E-03 | APP, PTPN11, PTPN6, SRC |
BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 7.148E-05 | 3.345E-03 | ABCG2, APP, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
BP | GO:0050896; response to stimulus | GO:2001275; positive regulation of glucose import in response to insulin stimulus | 7.164E-05 | 3.345E-03 | NR1H4, PIK3R1, PTPN11 |
CC | GO:0044464; cell part | GO:0034774; secretory granule lumen | 7.438E-05 | 3.461E-03 | ALOX5, APP, MAPK1, MPO, NFKB1, PKM, PTPN6, PYGL, TTR |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 7.478E-05 | 3.472E-03 | ALOX5, CXCR1, GAA, MAPK1, MMP9, MPO, NFKB1, PKM, PTPN6, PYGL, TTR |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 7.617E-05 | 3.529E-03 | AKR1B1, AKT1, CD38, HSD17B2, KDR, MMP2, NR1H4, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 7.985E-05 | 3.661E-03 | AKT1, LMNA, MAPT, MET, NEK2, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 8.781E-05 | 3.967E-03 | MCL1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.781E-05 | 3.967E-03 | ALOX12, ALOX15, ALOX5 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.087E-05 | 4.022E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 9.087E-05 | 4.022E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.087E-05 | 4.022E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.087E-05 | 4.022E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 9.087E-05 | 4.022E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.087E-05 | 4.022E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 9.087E-05 | 4.022E-03 | GPBAR1, NR1H4 |
BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 1.027E-04 | 4.455E-03 | AXL, FLT3, GLO1, MMP9, PARP1, PIK3R1, PTPN2, RORC |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.062E-04 | 4.552E-03 | AURKB, CDK1, PKN1 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.100E-04 | 4.682E-03 | ADRA2C, AKT1, ALOX12, APP, AXL, CA2, CAMK2B, CDK1, CYP1B1, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, NR1H4, PIK3R1, PIM1, PTK2, PTPN2, PTPN6, PTPRF, SRC, STAT6, XDH |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.113E-04 | 4.726E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 1.202E-04 | 5.071E-03 | AKR1B1, APEX1, GAA, HIF1A, NOX4, PARP1, PTPN11, SRC |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.322E-04 | 5.502E-03 | IGF1R, KDR, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.380E-04 | 5.733E-03 | AKT1, CYP1B1, DAPK1, GSK3B, MAPT, MCL1, MMP9, NOX4, PTPN2, SRC, TP53, XDH |
BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 1.401E-04 | 5.810E-03 | ADRA2A, AKT1, APP, CA2, CA7, CAMK2B, DAPK1, DRD4, MMP9, NPSR1, PLA2G1B, PTPN6 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.436E-04 | 5.921E-03 | AKT1, MAPT, NOX4, TP53, XDH |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 1.456E-04 | 5.983E-03 | APP, AURKB, GSK3B, MET, MMP9, PTPRF, SRC |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.506E-04 | 6.142E-03 | ADRA2A, CD38, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.636E-04 | 6.583E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PKM, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.811E-04 | 7.130E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.811E-04 | 7.130E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.811E-04 | 7.130E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.811E-04 | 7.130E-03 | TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.811E-04 | 7.130E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.811E-04 | 7.130E-03 | CYP1A1, CYP1A2 |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 1.852E-04 | 7.261E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 1.903E-04 | 7.414E-03 | ADRA2C, AKT1, APP, AXL, CA2, CAMK2B, CDK1, GSK3B, HIF1A, KDR, L3MBTL1, MAPK1, MAPT, NFKB1, PARP1, PIK3R1, PTK2, PTPN2, PTPN6, PTPRF, RORC, XDH |
BP | GO:0009987; cellular process | GO:0032872; regulation of stress-activated MAPK cascade | 1.952E-04 | 7.565E-03 | AKT1, APP, IGF1R, MAPK1, PKN1, PTPN1, XDH |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.044E-04 | 7.808E-03 | CYP1A1, POLB, TP53 |
BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 2.247E-04 | 8.511E-03 | AURKB, GSK3B, MET, NEK2, PTPRF, TNKS |
BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 2.274E-04 | 8.583E-03 | AKT1, GAA, GSK3B, PYGL |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.274E-04 | 8.583E-03 | NOX4, PARP1, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0032461; positive regulation of protein oligomerization | 2.700E-04 | 9.937E-03 | MMP1, MMP3, TP53 |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.700E-04 | 9.937E-03 | DRD4, NMUR2, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.700E-04 | 9.937E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 2.702E-04 | 9.937E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.702E-04 | 9.937E-03 | AKT1, DAPK1, LMNA, MCL1, SRC |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.190E-22 | 1.296E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.858E-16 | 8.503E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.989E-15 | 4.343E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.299E-22 | 1.409E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.468E-13 | 2.382E-11 | CAMK2B; SRC; MMP2; PTPN11; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; PTPN6; TP53; MET |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.111E-10 | 1.358E-08 | PTPN1; CSNK2A1; SRC; MAPK1; PTPN6; ACP1; MET; PTPRF; IGF1R |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.223E-09 | 1.037E-07 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; MET; TP53 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.991E-09 | 9.605E-08 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.585E-09 | 9.978E-08 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.139E-07 | 2.683E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; ESR2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.471E-08 | 6.814E-07 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.892E-07 | 4.652E-06 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R; MCL1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.251E-07 | 2.683E-06 | PTPN1; GSK3B; AKT1; PTPN11; PIK3R1; PYGL; NFKB1; PTPRF |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.636E-07 | 4.652E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.672E-07 | 4.652E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.945E-07 | 6.362E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.230E-07 | 5.896E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.578E-07 | 9.042E-06 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1; MCL1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.332E-07 | 6.432E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.919E-07 | 6.720E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.179E-06 | 1.083E-05 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.023E-06 | 9.868E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; ESR2 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 8.902E-07 | 9.042E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.397E-06 | 1.100E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.301E-06 | 1.100E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.139E-06 | 1.516E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD11B1; CYP2C8; PKM; AKR1B10; ALOX5; HSD17B2; CYP1A2; CYP1A1; CD38; ALPI; XDH |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.337E-06 | 1.100E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.135E-06 | 1.516E-05 | PIM1; AKT1; PTPN6; STAT6; PTPN11; PIK3R1; PTPN2; MCL1 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.648E-06 | 2.133E-05 | PLA2G1B; KDR; AKT1; MAPK1; PTPN11; PIK3R1; MET; NFKB1; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.351E-06 | 1.565E-05 | APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.425E-06 | 1.100E-05 | AKT1; MAPK1; PTPN11; PIK3R1; MET; HIF1A |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.426E-06 | 2.512E-05 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1; CDC25B; MCL1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.199E-06 | 1.516E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.333E-06 | 2.010E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.277E-07 | 5.896E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.591E-06 | 1.613E-05 | AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.591E-06 | 1.613E-05 | GSK3B; AKT1; MAPK1; PTPN6; PIK3R1; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.444E-06 | 3.991E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.307E-05 | 6.305E-05 | GSK3B; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.454E-05 | 6.682E-05 | POLB; PKM; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 9.839E-06 | 4.997E-05 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL; PTPRF |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.709E-05 | 7.671E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.438E-05 | 6.682E-05 | CDK1; AKT1; MAPK1; PIK3R1; CDC25B; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.126E-06 | 2.827E-05 | HSD11B1; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.020E-05 | 8.499E-05 | GSK3B; AKT1; MAPK1; PTPN6; PIK3R1; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.778E-05 | 1.117E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.227E-05 | 6.070E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.488E-06 | 4.428E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.407E-04 | 4.850E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.538E-05 | 1.717E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 9.113E-05 | 3.257E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.054E-05 | 2.933E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.751E-05 | 1.117E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.883E-04 | 9.430E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.261E-04 | 1.032E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.501E-04 | 5.081E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.026E-05 | 8.499E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.848E-05 | 3.456E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.181E-05 | 1.253E-04 | CXCR1; SRC; PTPN11; MET; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.488E-05 | 1.717E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.026E-05 | 8.499E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.322E-04 | 1.303E-03 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.069E-04 | 1.977E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1; TSHR |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.322E-04 | 1.303E-03 | MMP2; PTPN11; PIK3R1; MMP9; PTK2 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.491E-04 | 1.842E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.065E-03 | 2.815E-03 | CXCR1; AKT1; MAPK1; PTPN11; PIK3R1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.000E-03 | 2.682E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.607E-03 | 4.135E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.048E-03 | 5.068E-03 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.504E-03 | 5.749E-03 | AKT1; MAPK1; MAPT; TP53; NFKB1; CDC25B |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.654E-03 | 5.955E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.509E-03 | 5.749E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.902E-03 | 4.792E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.448E-03 | 3.776E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.124E-03 | 5.123E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 3.187E-03 | 6.990E-03 | CSNK2A1; CDK1; PTPN11; TP53; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.701E-03 | 5.991E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.124E-03 | 5.123E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.999E-04 | 9.646E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.363E-03 | 5.561E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.532E-03 | 5.749E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 4.195E-03 | 8.995E-03 | SRC; AKT1; MAPK1; PIK3R1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.318E-03 | 9.158E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.149E-04 | 2.215E-03 | SRC; PIK3R1; MET; PTK2 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.444E-03 | 9.322E-03 | GSK3B; CDK1; TP53; CDC25B |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.079E-04 | 1.270E-03 | CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 4.836E-03 | 1.004E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.279E-02 | 2.223E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.124E-04 | 1.521E-03 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.541E-03 | 1.102E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.689E-03 | 1.120E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.712E-04 | 1.645E-03 | CA2; NR1H4; CYP3A4; ABCG2 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 5.995E-03 | 1.157E-02 | MAPK1; PTPN6; PTPN11; PIK3R1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 8.837E-03 | 1.609E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 8.248E-03 | 1.516E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.149E-03 | 1.327E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.664E-02 | 2.722E-02 | NMUR2; ADRA2C; ADRA2A; DRD4; TSHR |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.800E-02 | 4.394E-02 | SRC; MAPK1; PIK3R1; PTK2 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.897E-02 | 4.472E-02 | AKT1; PIK3R1; IGF1R |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.655E-02 | 2.722E-02 | CAMK2B; GSK3B; MAPK1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.655E-02 | 2.722E-02 | PIK3R1; NFKB1; PTK2 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.364E-02 | 2.330E-02 | AKT1; MAPK1; PIK3R1 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.485E-02 | 2.514E-02 | CA2; PLA2G1B; CD38 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.364E-02 | 2.330E-02 | CSNK2A1; PARP1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.176E-02 | 2.082E-02 | SRC; CDK1; MAPK1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.105E-02 | 1.975E-02 | MAPK1; PKN1; NFKB1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 5.798E-03 | 1.130E-02 | AKT1; MAPK1; PIK3R1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.059E-03 | 1.323E-02 | MAPK1; PTPN6; NFKB1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.285E-03 | 1.201E-02 | AKT1; PTPN11; NFKB1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.895E-03 | 1.005E-02 | AKT1; PIK3R1; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.359E-03 | 7.284E-03 | AKT1; PIK3R1; TSHR |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.112E-03 | 1.028E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 5.112E-03 | 1.028E-02 | RORC; STAT6; NFKB1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.101E-05 | 2.264E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.162E-03 | 5.151E-03 | PKM; MAPK1; PIK3R1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.912E-03 | 4.792E-03 | CYP3A4; XDH; CES2 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.832E-02 | 4.409E-02 | MAOA; NFKB1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.417E-02 | 3.824E-02 | AKT1; PIK3R1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.441E-04 | 1.591E-03 | AKR1B10; GAA; AKR1B1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.318E-02 | 3.697E-02 | ABCC1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.847E-02 | 2.996E-02 | MAPK1; PIK3R1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 7.227E-04 | 1.993E-03 | POLB; PARP1; APEX1 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.938E-02 | 3.117E-02 | PKM; GLO1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.048E-02 | 1.890E-02 | MAPK1; TP53 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.267E-02 | 2.223E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.587E-02 | 2.663E-02 | AKR1B10; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.667E-03 | 1.261E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.806E-04 | 9.337E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Melanoma | C43 | PARP1; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; NFKB1; GPBAR1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; PKM; AKT1; FLT3; CA9; MMP2; SRC; IGF1R; AURKB; HIF1A; MAPK1; MMP9; PTK2; TP53; KDR; KDR; KDR |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; MMP3; CAMK2B; MMP1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; CD38; AURKB; TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; MCL1; CSNK2A1; AKT1; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; CD38; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; CDC25B; PTK2; TP53; KDR; APP |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; CYP3A4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; MMP13; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; PTPN1; GSK3B |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; MMP12; ADRA2C |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; MMP1 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; KDR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; APP |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MMP12 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |